Clinical Study
Endoscopic-Ultrasound-Guided Tissue Sampling Facilitates the Detection of Local Recurrence and Extra Pelvic Metastasis in Pelvic Urologic Malignancy
Table 1
Clinical and EUS features of patients with primary disease, local recurrence or extra pelvic metastatic urological disease.
| | Age & gender | Prior cancer diagnosis | Referral source | FNA location | Targeted biopsy or incidental finding | FNA passes | Cytologic interpretation | Immuno-staining1 | Final diagnosis |
| 1 | 84 M | Bladder | General surgery | Iliac LN | Targeted biopsy | 5 | Positive | CK7, CK20, OSCAR, p63 | Recurrent bladder | 2 | 82 M | Bladder (T1) | Colorectal surgery | Bladder mass | Incidental | 3 | Positive | CK7, CK20, CK903 | Recurrent bladder | 3 | 82 M | Bladder G3 muscle invasive | Urology | Perirectal space | Targeted biopsy | 3 | Positive | CK7, CK20 | Recurrent bladder | 4 | 64 M | No | Urology | Perirectal space | Targeted biopsy | 1 | Positive | NA | Bladder cancer | 5 | 68 M | Prostate (T3b) & perianal Crohns disease | Urology | Perirectal space | Targeted biopsy | 3 | Negative | NA | Recurrent prostate following surgical evaluation | 6 | 66 M | Prostate Gleason 3 + 3 | Urology | Perirectal LN | Targeted biopsy | 3 | Positive | PSA, PACP | Recurrent prostate | 7 | 77 M | Prostate Gleason 4 + 4 | Urology | Perirectal LN | Targeted biopsy | 5 | Positive | PSA, PACP | Prostate cancer | 8 | 95 M | Bladder G1 | Gastroenterology | Perirectal LN | Targeted biopsy | 3 | Positive | PSA | Prostate cancer | 9 | 60 M | Bladder | Gastroenterology | Rectal wall | Targeted biopsy | 3 | Suspicious | NA | Recurrent bladder³ | 10 | 53 M | Prostate Gleason 3 + 3 | Urology | Perirectal space | Targeted biopsy | 2 | Positive | PSA, PACP | Recurrent prostate | 11 | 73 M | Bladder G2 superficial | Urology | Rectal wall | Targeted biopsy | 5 | Positive | NA | Recurrent bladder³ | 12 | 54 M | Bladder G3 muscle invasive | Gastroenterology | Rectal wall | Targeted biopsy | 3 & TCB (4) | Positive | CK7, CK20 | Recurrent bladder³ | 13 | 54 M | No | Urology | Perirectal space | Targeted biopsy | 4 | Negative | NA | left seminal vesicle | 14 | 55 M | Bladder G3 muscle invasive | Urology | Rectal wall | Targeted biopsy | 2 & TCB (2) | Positive | CK7, CK20, CK903 | Recurrent bladder³ | 15 | 70 F | Bladder G3 muscle invasive | Urology | Rectal wall | Targeted biopsy | 9 | Positive | Keratin AE1/AE3 | Recurrent bladder | 16 | 86 M | Prostate | Urology | Perirectal space | Targeted biopsy | 2 | Positive | NA | Recurrent prostate | 17 | 40 M | Bladder G3 muscle invasive | Urology | Mediastinal LN | Targeted biopsy | 4 | Positive | NA | Metastatic bladder | 18 | 37 M | Testicular embryonal and yolk sac tumor | Urology | Duodenal wall | Targeted biopsy | 5 & TCB (3) | Positive | NA | Metastatic nonseminomatous germ cell tumor consistent with embryonal carcinoma | 19 | 72 M | Prostate Gleason 3 + 3 | Medical oncology | Subcarinal LN | Targeted biopsy | 3 | Positive | PSA, PACP° | Metastatic prostate |
|
|
1CK7, 20, 903: Cytokeratin 7, 20, 903. OSCAR: Monoclonal Antibody against Cytokeratin. PSA: Prostate-specific antigen. PACP: Human prostatic acid phosphatase. Keratin AE1/AE3: detects CK1–8, 10, 14–16 and 19.
°Negative for CK7, TTF-1 and CDX2. ²LN: lymph node. ³Linitis plastica.
|